Clinical data suggest that treatment with anti–CTLA-4 and anti–PD-1 antibodies alters and diversifies the TCR repertoire within the tumor microenvironment and is positively associated with antitumor responses (3–5). This evidence concerns the gene CTLA4 and neoplasm.